Highline Wealth Partners’s Genmab GMAB Stock Holding History

Highline Wealth Partners’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-122	Closed	-$2.39K	–	969
2025 Q1	$2.39K	Buy	+122	New	+$2.56K	﹤0.01%	597

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Highline Wealth Partners's GMAB Position: Q2 2025 in Review

Highline Wealth Partners sold out of Genmab (GMAB) in Q2 2025, closing a stake of 122 shares — an estimated $2.39K sold.

Highline Wealth Partners first reported a position in GMAB in Q1 2025 and held it in 1 quarter. The position peaked at $2.39K in Q1 2025. 217 funds tracked by Wall St. Rank hold GMAB as of Q2 2025.

Highline Wealth Partners reported no remaining Genmab position as of Q2 2025 after selling out during the quarter.
Highline Wealth Partners sold 122 Genmab shares in Q2 2025, an estimated $2.39K.
Highline Wealth Partners first reported a position in Genmab in Q1 2025 and held it in 1 quarter.
Highline Wealth Partners's Genmab position peaked at $2.39K in Q1 2025.
217 funds tracked by Wall St. Rank held Genmab as of Q2 2025.

Based on Highline Wealth Partners's 13F filing for Q2 2025, filed 16 Jul 2025.